Fox Run Management’s Crescent Biopharma CBIO Stock Holding History

Fox Run Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-124	Closed	-$173K	–	753
2017 Q3	$173K	Buy	+124	New	+$146K	0.05%	620

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fox Run Management's CBIO Position: Q4 2017 in Review

Fox Run Management sold out of Crescent Biopharma (CBIO) in Q4 2017, closing a stake of 124 shares — an estimated $173K sold.

Fox Run Management first reported a position in CBIO in Q3 2017 and held it in 1 quarter. The position peaked at $173K in Q3 2017. 80 funds tracked by Wall St. Rank hold CBIO as of Q4 2017.

Fox Run Management reported no remaining Crescent Biopharma position as of Q4 2017 after selling out during the quarter.
Fox Run Management sold 124 Crescent Biopharma shares in Q4 2017, an estimated $173K.
Fox Run Management first reported a position in Crescent Biopharma in Q3 2017 and held it in 1 quarter.
Fox Run Management's Crescent Biopharma position peaked at $173K in Q3 2017.
80 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2017.

Based on Fox Run Management's 13F filing for Q4 2017, filed 18 Jan 2018.